Scopolamine (Devil's Breath)
Scopolamine (hyoscine, 'Devil's Breath') is a prescription anticholinergic and tropane alkaloid used medically for motion sickness and post-operative nausea, most familiar as the behind-the-ear Transderm Scop patch. It is not a DEA-scheduled controlled substance, but it is dangerous: at higher doses it causes disorientation, memory loss, and suggestibility, and it is best known for its use in drug-facilitated crimes via spiked drinks.
Overview
Scopolamine, also called hyoscine or 'Devil's Breath', is an anticholinergic medication and belladonna (tropane) alkaloid derived from nightshade-family plants such as henbane, jimsonweed, and datura. Medically it is FDA-approved for motion sickness and post-operative nausea and to reduce secretions before surgery, most commonly delivered as a low-dose transdermal patch worn behind the ear. It has a centuries-long history in medicine and a darker modern reputation tied to its use in crime, especially in parts of South America.
Source: FDA (DailyMed label); Wikipedia (CC-BY-SA); peer-reviewed literature (NIH/PMC)
Chemistry & mechanism of action
Scopolamine is a muscarinic acetylcholine receptor antagonist: it blocks the action of acetylcholine, a key neurotransmitter, in the brain and body. This anticholinergic action reduces nausea and secretions (its medical uses) but at higher exposures disrupts memory formation, attention, and awareness, producing confusion, amnesia, and a suggestible, disoriented state. It readily crosses the blood-brain barrier, which is why central effects are prominent.
Source: peer-reviewed literature (NIH/PMC); FDA
Effects
At the low, controlled doses of a medical patch, effects are mainly side effects: dry mouth, blurred vision, drowsiness, and dizziness. At higher or non-medical doses scopolamine produces disorientation, confusion, hallucinations, and a striking loss of memory for the period of intoxication, along with a passive, suggestible mental state. It is not typically described as euphoric or pleasant, which is part of why it has low recreational appeal.
Source: FDA (DailyMed label); peer-reviewed literature (NIH/PMC)
Risks & harms
Scopolamine's dangers fall into two categories. Medically and in overdose, it is a potent anticholinergic: too much causes a toxidrome of fast heart rate, dilated pupils, high temperature, urinary retention, confusion, toxic psychosis, vivid hallucinations, seizures, and at severe levels coma. The FDA label specifically warns against combining it with alcohol or other CNS depressants, which deepens confusion, disorientation, and sedation. The second, higher-profile danger is criminal: because scopolamine powder is colorless and tasteless, it has been used to spike victims' food or drinks in robberies, kidnappings, and sexual assaults, exploiting the drug's ability to render someone compliant and amnesic. Reports of incapacitation by 'blowing powder in the face' are pharmacologically dubious and likely exaggerated, but drink-spiking is a documented, real risk. There is no recreational safe-use pattern here; effects are unpleasant and the margin to serious toxicity is narrow. Anyone showing severe agitation, high fever, a racing heart, seizures, or unresponsiveness needs emergency care — call 911, and Poison Control at 1-800-222-1222 can advise. This page has not yet been medically reviewed.
Source: FDA (DailyMed label); peer-reviewed literature (NIH/PMC); SAMHSA
Legal status (US)
In the United States, scopolamine is a prescription medication but is NOT a DEA-scheduled controlled substance — the controlled-substances list is based on abuse potential, and scopolamine's unpleasant effects give it low recreational appeal. It remains prescription-only, so manufacturing, distributing, or possessing it without a valid prescription is unlawful, and because of its role in drug-facilitated crime, possession without a prescription can draw investigation for related offenses. It occurs naturally in nightshade-family plants (datura, henbane), which are themselves legal to grow in most places but dangerous to consume. Follow a prescriber's directions and local law; consult FDA resources for specifics. This page has not yet been medically reviewed.
Source: FDA; DEA; US federal law
Drug laws and enforcement change and vary by country. This is not legal advice. Always confirm with the destination’s embassy or official drug authority before traveling — penalties can be severe, including imprisonment.
Before you travel
Verify current rules with the destination country’s official drug authorityand your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulatein the destination immediately — notthe destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
Images
Visual references coming soon.
If it’s too intense
If an experience becomes overwhelming, the goal is to stay safe and let it pass — most difficult experiences ease as the drug wears off.
- Get to a calm, safe space with someone you trust who is sober and can stay with you.
- Cool down if you’re overheating — move somewhere cool, remove extra layers, rest. Overheating is especially a risk with stimulants and MDMA.
- Sip water to thirst — but don’t over-hydrate. Drinking large amounts of plain water (especially after MDMA) can dangerously dilute your blood sodium (hyponatremia). Electrolytes help more than volume.
- Slow your breathing — long, slow exhales help settle a racing heart and anxiety.
- A sugary drink, fruit juice, or a snack can ease shakiness and the anxiety that comes with low blood sugar.
- Do not take more, and do not add another substance to manage it. Redosing or adding something else (including a sedative like a benzodiazepine) can make things worse, not better.
Source: general harm-reduction guidance from SAMHSA, NIH/NIDA, and MedlinePlus, in our own words. Draft — not yet medically reviewed.
Forensic dossier
Draft · every field is source-cited or marked “Unknown — pending review”Identity
- PubChem CID
- 3000322PubChem PUG-REST ↗ · retrieved 2026-06-18
- IUPAC name
- [(1S,2S,4R,5R)-9-methyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-7-yl] (2S)-3-hydroxy-2-phenylpropanoatePubChem PUG-REST ↗ · retrieved 2026-06-18
- Molecular formula
- C17H21NO4PubChem PUG-REST ↗ · retrieved 2026-06-18
- SMILES
- CN1[C@@H]2CC(C[C@H]1[C@H]3[C@@H]2O3)OC(=O)[C@H](CO)C4=CC=CC=C4PubChem PUG-REST ↗ · retrieved 2026-06-18
- InChIKey
- STECJAGHUSJQJN-USLFZFAMSA-NPubChem PUG-REST ↗ · retrieved 2026-06-18
- Synonyms / aliases
- devil's breath, hyoscine, Scopace, Boro-Scopol, scopolamine, Hyoscine, (-)-Hyoscine, Scopine tropate, Transderm-Scop, (-)-Scopolamine, Scopine (-)-tropate, AtrochinPubChem PUG-REST + seed aliases ↗ · retrieved 2026-06-18
Composition
- Composition
- N/A — single compound (see Identity)
Physical / pill characteristics
- Dosage form
- Unknown — pending review (no Rx/OTC label; illicit — pill visuals = FIRST-PARTY submissions only, never generated or scraped)
- Route
- Unknown — pending review
- Shape
- Unknown — pending review
- Color
- Unknown — pending review
- Imprint
- Unknown — pending review
- Score
- Unknown — pending review
Scheduling & legal status
- US schedule
- Unknown — pending review
- International
- See EMCDDA/EUDA + WHO — synthesize per jurisdictionEMCDDA / EUDA ↗ · retrieved 2026-06-18
Effects
- Effects
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Risks
- Risks
- Cited source pending synthesis — author in our words from NIDA/MedlinePlus on review (NOT auto-generated)NIDA + MedlinePlus ↗ · retrieved 2026-06-18
Interactions
- Interactions
- Unknown — pending review
Dosage
Pending medical reviewer
